## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity		
LYNAS CORPORATION LTD		
ADNI		
ABN 27 009 066 648		
27 009 000 040		

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

†Class of \*securities issued or to be issued

Unlisted Performance Rights

Number of \*securities issued or to be issued (if known) or maximum number which may be issued

12,686,047 Performance Rights

Principal terms of the 3 +securities (eg, options, exercise price and expiry date; if paid +securities, the partly amount outstanding and due dates for if payment; +convertible securities, the conversion price and dates for conversion)

The Employee Performance Rights are subject to the Performance Conditions specified in the Lynas AGM Notice 2016 and are exercisable without further consideration on the dates specified in section 9.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	N/A
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	The Performance Rights were valued as follows:
		FY16 STI: \$0.0645 per Performance Right LTI: \$0.0645 per Performance Right
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To be granted for the benefit of selected senior employees as incentive rewards.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	
6c	Number of *securities issued without security holder approval under rule 7.1	
6d	Number of *securities issued with security holder approval under rule 7.1A	

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of securities issued under an exception in rule 7.2		
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.		
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	_	hts were approved by ovember 2016, and will from that date.
			· .
0	Ni1 +1 C 11	Number	+Class
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	3,488,438,369	Ordinary shares

9	Number a	nd	+class
	of all <sup>+</sup> secu	riti	es not
	quoted o	n	ASX
	(including		the
	+securities		in
	section	2	if
	applicable)		

Number	<sup>+</sup> Class
360,864	Class 1 Employee Performance Rights
	exercisable for no further consideration on
	or before 23 September 2018
9,443,395	Class 2 Employee Performance Rights
	exercisable for no further consideration on
	or before 23 September 2019
0.52.0.50	Sign-On Performance Rights exercisable for
862,069	no further consideration on or before 23
	September 2017
1,086,957	Performance Bonus Performance Rights
	exercisable for no further consideration on
	or before 23 September 2017
6,226,416	LTI Performance Rights exercisable for no
0,220,110	further consideration on or before 23
	September 2019
1 161 206	Performance Bonus Performance Rights
4,464,286	exercisable for no further consideration on or
	before 6 May 2018
25 606 020	STI Performance Rights exercisable for no
25,686,920	further consideration in the first employee
	trading window after 28 July 2016
	I TI Douformance Dights eversionable for no
47,709,315	LTI Performance Rights exercisable for no further consideration on or before 18
	September 2020
	September 2020
10,743,941	STI Performance Rights exercisable for no
- 4 4.	further consideration in the first employee
	trading window after 30 August 2017
22 716 709	ITI Dorformanco Dighta oversigable for
23,716,708	LTI Performance Rights exercisable for no further consideration on or before 30 August
	2021
225,000,000	2.75% Convertible Bonds due 30 September
	2018
174,365,466	Warrants exercisable at \$0.038 on or before
, , 3	30 September 2018

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
Part	: 2 - Bonus issue or pro ra	ıta issue
11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	

22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if	
	applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Despatch date	

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities Type of securities 34 (tick one) (a) Securities described in Part 1 (b) All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of the 35 additional \*securities, and the number and percentage of additional \*securities held by those holders If the +securities are +equity securities, a distribution schedule of the additional 36 +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional +securities 37

### Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	
39	Class of *securities for which quotation is sought	

40	Do the <sup>+</sup> securities rank equally in all respects from the date of allotment with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?		
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in clause 38)		

Appendix 3B Page 8 o1/08/2012

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 30 November 2016

Company Secretary)

Print name: ANDREW ARNOLD

== == == ==

01/08/2012 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.